Kura Oncology, Inc.
KURA
$9.22
-$0.52-5.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.37% | 25.24% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.37% | 25.24% | -- | -- | -- |
| Cost of Revenue | 37.44% | 47.75% | 2.57% | 11.24% | 25.19% |
| Gross Profit | -55.36% | -58.20% | 42.09% | 32.31% | 19.68% |
| SG&A Expenses | 57.41% | 55.60% | 55.96% | 45.02% | 42.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.45% | 50.20% | 58.09% | 51.42% | 47.77% |
| Operating Income | -56.18% | -57.16% | -10.26% | -9.80% | -10.75% |
| Income Before Tax | -63.93% | -61.88% | -8.65% | -7.25% | -6.88% |
| Income Tax Expenses | -96.48% | -85.28% | -- | -- | -- |
| Earnings from Continuing Operations | -61.95% | -60.17% | -9.79% | -8.49% | -8.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.95% | -60.17% | -9.79% | -8.49% | -8.21% |
| EBIT | -56.18% | -57.16% | -10.26% | -9.80% | -10.75% |
| EBITDA | -56.28% | -57.32% | -10.31% | -9.84% | -10.82% |
| EPS Basic | -60.19% | -57.04% | -5.18% | -1.26% | 3.95% |
| Normalized Basic EPS | -55.46% | -52.05% | -5.06% | -1.33% | 3.60% |
| EPS Diluted | -60.19% | -57.04% | -5.18% | -1.26% | 3.95% |
| Normalized Diluted EPS | -55.46% | -52.05% | -5.06% | -1.33% | 3.60% |
| Average Basic Shares Outstanding | 1.08% | 1.76% | 4.47% | 7.37% | 12.93% |
| Average Diluted Shares Outstanding | 1.08% | 1.76% | 4.47% | 7.37% | 12.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |